- Home
- ISRG vs TMO Comparison
ISRG vs TMO Comparison
Compare ISRG & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | TMO |
|---|---|---|
| Founded | 1995 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.9B | 216.4B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | ISRG | TMO |
|---|---|---|
| Price | $534.76 | $620.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $609.29 | ★ $637.78 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 01-22-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 0.28% |
| EPS Growth | ★ 21.56 | 8.54 |
| EPS | 7.56 | ★ 17.32 |
| Revenue | $9,612,000,000.00 | ★ $43,736,000,000.00 |
| Revenue This Year | $21.14 | $4.33 |
| Revenue Next Year | $15.00 | $4.98 |
| P/E Ratio | $70.78 | ★ $35.73 |
| Revenue Growth | ★ 22.18 | 3.22 |
| 52 Week Low | $425.00 | $385.46 |
| 52 Week High | $616.00 | $629.87 |
Technical Indicators
Market Signals| Indicator | ISRG | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 62.94 |
| Support Level | $528.00 | $594.30 |
| Resistance Level | $553.74 | $629.87 |
| Average True Range (ATR) | 13.11 | 14.61 |
| MACD | -5.59 | 2.04 |
| Stochastic Oscillator | 10.06 | 82.57 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).